LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients.

Background: To validate the subdivision of intermediate-risk (IR) prostate cancer (PCa) into favorable intermediate-risk (FIR) and unfavorable intermediate-risk (UIR) PCa in a historical patient cohort and to compare 2 different radiotherapy regimens.

Methods: Patients with intermediate-risk (IR) PCa, treated either by J-LDR-brachytherapy monotherapy (BT) or by combined-modality radiation therapy (CRT), were retrospectively subclassified into FIR and UIR and reanalyzed with regard to biochemical recurrence-free survival (BRFS), metastasis-free survival (MFS), and prostate cancer-specific survival (CSS). Kaplan-Meier product-limit method and log-rank tests were applied to estimate survival probabilities and compare survival, respectively.

Definitions of "Cure" After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?

Purpose: The aim of this study was to compare a surgical with a Phoenix-derived definition of at 4 years after treatment by J low-dose-rate brachytherapy (LDR-BT) in patients with low- and intermediate-risk prostate cancer.

Methods And Materials: A total of 427 evaluable men with low-risk (62.8%) and intermediate-risk (37.